Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa

Lancet

Volumn 353, Issue 9147, 1999, Pages 98-102

  Whittle, Hilton C ^a   Aaby, Peter ^b,c   Samb, Badara ^b,d   Jensen, Henrick ^c   Bennett, John ^e   Simondon, Francois ^b  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (Senegal)

^c DEPARTMENT OF EPIDEMIOLOGY RESEARCH   (Denmark)

^d INSERM   (France)

^e EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; MEASLES VACCINE;

AFRICA; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL FEATURE; DISEASE SEVERITY; EPIDEMIC; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; IMMUNITY; MEASLES; NORMAL HUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 0033537354     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)02364-2     Document Type: Article

References (30)

1. Panum PL. Observations made during the epidemic of measles in the Faroe Islands in the year 1846. New York: New York Public Health Association, 1940.
2. Krugman S Further attenuated measles vaccine: characteristics and use. Rev Infect Dis. 5:1983;477-481.
3. Chen RT, Markowitz LE, Albrecht Pet al. Measles antibody:re-evaluation of protective titres. J Infect Dis. 162:1990;1036-1062.
4. Gustafson TL, Lievens AW, Brunell PAet al. Measles outbreak in a fully immunised secondary school population. N Engl J Med. 316:1987;771-774.
5. Samb B, Aaby P, Whittle HCet al. Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. Pediatr Infect Dis J. 14:1995;203-209.
6. Bin D, Zhihui C, Qichang Let al. Duration of immunity following immunisation with live measles vaccine: 15 years of observation in Zheyiang Province China. Bull World Health Organ. 69:1991;415-423.
7. Markowitz LE, Preblud SR, Fine PEM, Orenstein WA Duration of live measles vaccine induced immunity. Pediatr Infect Dis J. 9:1990;101-110.
8. Samb B, Aaby P, Whittle H, Coll-Seck AM, Simondon F Decline in measles case fatality ratio after the introduction of measles immunisation in rural Senegal. Am J Epidemiol. 145:1997;51-57.
9. Mulholland K Measles and pertussis in developing countries with good vaccine coverage. Lancet. 345:1995;305-307.
10. Orenstein WA, Bernier RH, Hinman AR Assessing vaccine efficacy in the field. Epidemiol Rev. 10:1988;212-241.
11. Whittle H, Hanlon P, O'Neill Ket al. Trial of high-dose Edmonston-Zagreb measles vaccine in The Gambia: antibody response and side effects. Lancet. ii:1988;811-814.
12. Samb B, Aaby P, Whittle H, Coll Seck AM, Simondon F Protective efficacy of high-titre measles vaccines administered from the age of five months in rural Senegal. Trans R Soc Trop Med Hyg. 87:1993;697-701.
13. Cisse B, Aaby P, Simondon F, Samb B, Soumare M, Whittle H. The role of schools in the transmission of measles in rural Senegal. Implications for measles control in developing countries. Am J Epidemiol (in press).
14. Chahnazarian A, Becker C, Delaunay V, et al. Population et santè à Niakhar, 1984-1991. Dakar: ORSTOM, 1992.
15. Garenne M, Leroy O, Beau JP, Sene I Child mortality after high-titre measles vaccines: prospective study in Senegal. Lancet. 338:1991;903-907.
16. Garenne M, Aaby P Pattern of exposure and measles mortality in Senegal. J Infect Dis. 161:1990;1088-1094.
17. Whittle HC, Mann G, Eccles Met al. Effects of dose and strain of vaccine on success of measles vaccination of infants aged 4-5 months. Lancet. i:1998;866-963.
18. Bennett J, Whittle H, Samb B, Cisse B, Simondon F, Aaby P. Seroconversions in unvaccinated infants: further evidence for sub-clinical measles from vaccine trials in Niakhar, Senegal. Int J Epidemiol (in press).
19. Aaby P, Knudsen K, Jensen TG et al. Measles incidence, vaccine efficacy, and mortality in two urban African areas with high vaccination coverage. J Infect Dis. 162:1990;1043-1048.
20. Outlaw M, Jaye A, Whittle HC, Pringle CR Clustering of haemagglutinin gene sequences of measles viruses isolated in The Gambia. Virus Res. 48:1997;125-131.
21. Rima BK, Earle JAP, Yeo RP et al. Temporal and geographical distribution of measles virus genotypes. J Gen Virol. 76:1995;1173-1180.
22. Norrby E The paradigms of measles vaccinology. Curr Top Microbiol Immunol. 191:1995;167-180.
23. McMurray DN, Loomis SA, Casazza LJ, Rey H Influence of moderate malnutrition on morbidity and antibody response following vaccination with live attenuated measles virus vaccine. Bull Panam Health Organ. 13:1979;52-57.
24. Stetler HC, Orenstein WA, Bernier RH Impact of revaccinating children who initially received measles vaccine before 10 months of age. Paediatrics. 77:1986;471-476.
25. Cohen S, McGregor IA, Carrington S γ-globulin and acquired immunity to human malaria. Nature. 192:1961;733-787.
26. Whittle HC, Aaby P, Samb B, et al. Poor serological responses 5-7 years after immunisation with high and standard titre measles vaccines. Pediatr Infect Dis J (in press).
27. Anders JF, Jacobson RM, Poland GA, Jacobsen SJ, Wollan PC Secondary failure rates of measles vaccines: a meta analysis of published studies. Pediatr Infect Dis J. 15:1996;62-66.
28. Forster SO, Pifer JM Mass measles control in West and Central Africa. Afr J Med Sci. 2:1971;151-158.
29. de Quadros CA, Olive JM, Hensh BSet al. Measles elimination in the Americas. JAMA. 275:1996;224-229.
30. Aaby P, Bukh J, Lisse IM, Smits AJ Overcrowding and intensive exposure as determinants of measles mortality. Am J Epidemiol. 120:1984;49-63.